Inspiremd Inc. · NASDAQ:NSPR
Inspiremd — Investor Presentation (July 2020)
23 slides from Inspiremd's investor presentation, Jul 8, 2020
Slide 1: InspireMD
lon stained bolic Protect Em inspireMD
Slide 2: Disclaimers
—t Disclaimers This presentation contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements
Slide 3: About InspireMD
mM About InspireMD InspireMD is a commercial-stage medical device company focused on stroke prevention in patients with carotid artery disease and treatment of other minimally 3 MicroNet™ is a proprietary platform comprised of thin, invasive indications utilizing an integrated 20-micron polyethylene
Slide 4: Our Leadership
™@ Our Leadership Mr. Slosman has over 30 years of experience in the medical device industry with focused Marvin L. Slosman leadership in commercialization and international market development President and CEO in both public and privately held companies. He has had senior management roles @ in a va
Slide 5: InspireMD Pipeline
InspireMD Pipeline Peripheral Treatment: Neuro Treatment: References: 1. Musialek P et al. PARADIGM-Extend Prospective Academic Trial: Accumulating long-term evidence for MicroNet-covered stent safety and stroke prevention efficacy. P ° Presentation at ESC Congress 2019, Paris, France, 31 August 201
Slide 6: Endovascular Procedures: Landscape and InspireMD Potential
Endovascular Procedures: Landscape and InspireMD Potential CAROTID CAD market ARTERY potential DISEASE open to endo conversion 20% Endo® ww: 614K STILL AWAITING prossainas CONVERSION in 2018 (estimated) 5 80% Surgical? Already have been converted to endovascular procedures 1 Bekelis k, Gottlieb DJ,
Slide 7: Stroke is the Second Biggest Cause of Death Globally
Mi Stroke is the Second Biggest Cause of Death Globally An estimated 15 million people suffer from stroke annually’ *6.2 million deaths? *5 million people left permanently disabled? 10 %) * $34 billion associated with stroke management in the US 8 alone? 7 6 * ~85% of all strokes are ischemic stroke
Slide 8: THE PROBLEM: Risks with Existing Approaches to CAD
mi THE PROBLEM: Risks with Existing Approaches to CAD Surgery (CEA) and conventional Carotid Artery Stenting (CAS) both come with risks Carotid Endarterectomy (CEA) Carotid Artery Stenting (CAS) Risk of complications: Risk of complications: * Myocardial infarction risk? (heart attack) * Procedural a
Slide 9: THE PROBLEM: Risk of Embolism Following Conventional CAS
THE PROBLEM: Risk of Embolism Following Conventional CAS 90% occlusion of MRI of a pre-existing white Successful MRI reveals new multiple micro- the carotid matter infarction (obstruction) opening of the infarcts (obstructions) due to artery carotid artery liberation of embolic particles
Slide 10: OUR SOLUTION: Proprietary MicroNet Technology
Mi OUR SOLUTION: Proprietary MicroNet™ Technology New mesh covered stent that offers superior plaque coverage when compared to conventional stent approaches MicroNet™: an Embolic Prevention System (EPS) for Ultimate Thrombus Protection * Ultrathin flexible mesh sleeve, designed to expand seamlessly
Slide 11: Carotid Solution: Our Well Studied Mesh-Covered Technology
Mi Carotid Solution: Our Well Studied Mesh-Covered Technology More than 1,500 patients in Clinical Publications and Studies ee Highly-calcific car in symptomatic ar patients using the Analysis from the Initial Clinical Results and In Viero Testing of the New CGuard MicroNet-Covered “One-Size-Fits-Al
Slide 12: Timeline Growth: From Alternative Stent to New Gold Standard
Timeline Growth: From Alternative Stent to New Gold Standard YEAR STUDY PUBLICATION HIGHLIGHTS CGUARD™’S STANDING (known & anticipated) PARADIGM EXTEND * Large long-term study for all commers; CGuard™ study of long-term results UY cGuard™ demi OPTIMA * IVUS assessment after CGuard™; intended to demo
Slide 13: CGuard EPS Yields Superior Clinical Outcomes
Mi CGuard™ EPS Yields Superior Clinical Outcomes When compared with Conventional Stents and Surgery (CEA), CGuard™ trends Superior 30 Day DSM (Death, Stroke, Myocardial Infarction) . : * CGuard™ has a superior profile versus 6.00% i historical data on both conventional carotid 5.00% 4 stents and sur
Slide 14: A Billion Dollar Market Opportunity
MA Billion Dollar Market Opportunity Our MicroNet™-covered stents like CGuard™ could become the new gold standard * 2.2M diagnosed with carotid artery disease (CAD) WW carotid procedures today are Carotid procedures tomorrow could be primarily surgical: mostly minimally invasive with CGuard™ * 2017:
Slide 15: Commercial Footprint
™ Commercial Footprint (Dark Blue) * Active Selling in 39 Countries * Over 90% of sales are through channel partners / distributors * Short Term Expansion Brazil and France ¢ New countries development include Japan, S Korea and China * IDE Approval progressing with FDA; targeting initiation of US tr
Slide 16: Our Lead Product, CGuard - Advancing Rapidly
Mi Our Lead Product, CGuard™- Advancing Rapidly 31% growth of CGuard™ portfolio in Q4 2019 18,000 Total protected stents sold to date with excellent clinical results CGuard™ has potential to become the new standard-of- care for carotid indications *Achieved clinical milestones; neuroprotective vs ot
Slide 17: Our Advancement Roadmap / Milestones
Our Advancement Roadmap / Milestones Expand Broad Global *Launch CGuard™ in U.S. & China Embolic Protection Indications Advance AV Shunt (Reverse Flow) +Expanded indications for MicroNet™ *Demonstrate Superiority of CGuard™ in CAS *Grow above market in those served *Launch CGuard™ in Brazil *Complet
Slide 18: Our Robust Intellectual Property Portfolio
mM Our Robust Intellectual Property Portfolio Proprietary platform technology supported by IP Patent Rights Allowed USA 14 Rest of World 33 * InspireMD will continue to strengthen and broaden its patent protection globally to enable future pipeline products inspireMD july8,2020 ff 18
Slide 19: Our Business and Market Development
M™ Our Business and Market Development Strategic Targets for Merger or Acquisition Synergy > —Ct‘ L zzz > —C—s—CF i | =) : Boston, Medtronic Edwards CardinatHealth Scientific 5 Abbott —TERUMO BIOSENSORS NeRATONAL eae Teleflex: Zl) versie, (BORID | Met | 8 @MicroPort y Cc =] I SILKROAD> SYSTEMS, INC.
Slide 20: Silk Road - Comparison
Mi Silk Road- Comparison * Ticker SILK * $120 Million IPO ($20 per share) — April 2019 * Valuation at time of IPO — $600 Million * Current Stock Price - $37. 46 * Market Value today - $1.3 Billion * Revenue in 2019 - $63.4 Million (United States Only) Silk Road Stock Performance since IPO 30.000 nit
Slide 21: Summary Financials
Summary Financials NYSE AMERICAN NSPR Stock Price (7/6/20): Average volume: Shares outstanding (7/6/20): Shares outstanding including full conversion of preferred shares and prefunded warrants (7/6/20): Market capitalization including full conversion of preferred shares and prefunded warrants (7/6/2
Slide 22: Company Highlights
Mi Company Highlights Enabling a paradigm shift (CAS) in the treatment of carotid artery disease and stroke prevention CGuard™ EPS Breakthrough platform: Highly differentiated, with strong support from leading clinicians MicroNet™ technology that is elegantly simple, propriety and easily leveraged t
Slide 23: TQ S A A &
TQ S A A &